Manufacturing News

Neo-Bionica makes two new board appointments

Manufacturing News

Medical technology developer and contract manufacturer Neo-Bionica, which announced an investment of $5 million from Breakthrough Victoria earlier this month, has announced two new board appointments.

In a statement on Monday, the company said it had added Stéphane Chatonsky and Dr Colin White as non-executive directors.

“Their extensive expertise in innovation in MedTech, strategy and capital raising will be invaluable to Neo-Bionica as we enter our next phase of growth both domestically and internationally,” CEO Dr Ludovic Labat said.

Chatonsky’s current roles include as non-executive director at Cerulea Clinical Trials; Genetic Signatures (ASX: GSS); Drop Bio Health; and Brainmates, and has previously worked in investment banking with Lazard Freres and Macquarie Bank, strategy consulting at McKinsey, and in venture capital and private equity funds.

White is a former Managing Director at healthcare and diagnostic developer Invetech and Senior Vice President at Leica Biosystems, responsible for the company’s global advanced diagnostics business.

Neo-Bionica was established in 2021 – as a joint venture of the Bionics Institute and the University of Melbourne – to serve an identified need for local prototyping and manufacture of bionic and neurotech medical devices.

Picture: credit Neo-Bionica

Further reading

Neo-Bionica medical device centre launched in Melbourne

Breakthrough Victoria backs Neo-Bionica 

Growing Neo-Bionica announces new CTO

Neo-Bionica launches onshore critical medical manufacturing process

Share this Story
Manufacturing News

Stay Informed

Go to Top